2025-06-03-Bernstein-卫士健康公司（GH）_快速解读_Guardant的Shield检测现已纳入NCCN指南（积极因素）_检测间隔为3年（积极因素）_但作为二线选择（消极因素）_11页_502kb

Guardant Health (GH) Analysis Report Summary

Overview

This analysis covers Guardant Health Inc.'s Shield test, which was included in the National Comprehensive Cancer Network (NCCN) guidelines for colorectal cancer screening on May 30, 2025. The test is now recommended as a blood-based option with a three-year screening interval, serving as a second-line test. The report assesses the catalyst effects, revenue implications, and investment outlook.

Key Takeaways from QUICK TAKE

• Positive Catalyst: The inclusion is seen as a modest positive for Guardant Health, with the stock rising 4% on the day of announcement, outperforming the S&P 500 (-1%), though the guideline inclusion was not expected.
• Revenue Impact: NCCN guidelines may exert limited pressure on private payors for coverage but are unlikely to drive significant revenue growth compared to potential through American Cancer Society (ACS) guidelines, which could expedite payor coverage.
• Testing Interval: The three-year interval aligns with FDA and Guardant recommendations, supporting patient adherence and affordability, as annual testing would be cost-prohibitive due to the $1,495 price.
• Test Positioning: The NCCN explicitly designates Shield as a second-line test, which the report views as a minor negative, as Guardant management and models have positioned it as such, despite its FDA approval as a first-line test.

Investment Implications

• Rating and Target: Analyst maintains an Outperform rating with a $60 price target, based on discounted cash flow and EV/sales multiples, driven by the guideline inclusion and positive revenue potential.
• Performance Metrics: The stock has shown strong performance, with a 55.4% increase over the past year and a current market cap of $5.216 billion.
• Financial Projections: Adjusted EPS is expected to reach -$1.67 in 2026, with revenue growth at 21.9%, supported by market adoption in liquid biopsy for cancer screening.
• Risks: Key risks include early market saturation in circulating tumor DNA (ctDNA), competition from tests like Exact's, unsuccessful clinical trials for minimal residual disease (MRD) applications, slow physician adoption of blood-based screening, and funding needs for growth products.

Risks

• Market and Product Risks: The CGP (circulating tumor DNA) market may oversaturate, MRD and cancer screening products face competition or regulatory hurdles, and cash expenditures could exceed expectations.
• Adoption Challenges: Difficulties in convincing physicians to shift from traditional methods like colonoscopy could limit the uptake of Shield as the primary or second-line option.

Valuation

• Current Valuation: Based on a blended DCF at $63 and multiple model at $56, leading to a $60 price target with an adjusted P/E of 25.2 in 2026.
• Relative Performance: GH has outperformed the broader market, with a performance of 55.4% over the last year.

This summary highlights the guideline inclusion as a pivotal event, emphasizing both opportunities and residual challenges for Guardant Health.